Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Fig. 2

CSF cfDNA documents molecular characterization of EGFR-mutated NSCLC with LM. A Frequency of shared versus CSF-private or plasma-private alterations in paired CSF-plasma samples. B Discordance of on-target and off-target resistant mechanisms to osimertinib upon LM progression between paired CSF and plasma. CSF, cerebrospinal fluid; amp, amplification; mut, mutation

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us